FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4313209954> ?p ?o ?g. }

• W4313209954 endingPage "86" @default.
• W4313209954 startingPage "1" @default.
• W4313209954 abstract "The National Institute for Health and Care Excellence recommends macular laser to treat diabetic macular oedema with a central retinal subfield thickness of < 400 µm on optical coherence tomography. The DIAMONDS (DIAbetic Macular Oedema aNd Diode Subthreshold micropulse laser) trial compared standard threshold macular laser with subthreshold micropulse laser to treat diabetic macular oedema suitable for macular laser.Determining the clinical effectiveness, safety and cost-effectiveness of subthreshold micropulse laser compared with standard threshold macular laser to treat diabetic macular oedema with a central retinal subfield thickness of < 400 µm.A pragmatic, multicentre, allocation-concealed, double-masked, randomised, non-inferiority, clinical trial.Hospital eye services in the UK.Adults with diabetes and centre-involving diabetic macular oedema with a central retinal subfield thickness of < 400 µm, and a visual acuity of > 24 Early Treatment Diabetic Retinopathy Study letters (Snellen equivalent > 20/320) in one/both eyes.Participants were randomised 1 : 1 to receive 577 nm subthreshold micropulse laser or standard threshold macular laser (e.g. argon laser, frequency-doubled neodymium-doped yttrium aluminium garnet 532 nm laser); laser treatments could be repeated as needed. Rescue therapy with intravitreal anti-vascular endothelial growth factor therapies or steroids was allowed if a loss of ≥ 10 Early Treatment Diabetic Retinopathy Study letters between visits occurred and/or central retinal subfield thickness increased to > 400 µm.The primary outcome was the mean change in best-corrected visual acuity in the study eye at 24 months (non-inferiority margin 5 Early Treatment Diabetic Retinopathy Study letters). Secondary outcomes included the mean change from baseline to 24 months in the following: binocular best-corrected visual acuity; central retinal subfield thickness; the mean deviation of the Humphrey 10-2 visual field in the study eye; the percentage of people meeting driving standards; and the EuroQol-5 Dimensions, five-level version, National Eye Institute Visual Function Questionnaire - 25 and Vision and Quality of Life Index scores. Other secondary outcomes were the cost per quality-adjusted life-years gained, adverse effects, number of laser treatments and additional rescue treatments.The DIAMONDS trial recruited fully (n = 266); 87% of participants in the subthreshold micropulse laser group and 86% of participants in the standard threshold macular laser group had primary outcome data. Groups were balanced regarding baseline characteristics. Mean best-corrected visual acuity change in the study eye from baseline to month 24 was -2.43 letters (standard deviation 8.20 letters) in the subthreshold micropulse laser group and -0.45 letters (standard deviation 6.72 letters) in the standard threshold macular laser group. Subthreshold micropulse laser was deemed to be not only non-inferior but also equivalent to standard threshold macular laser as the 95% confidence interval (-3.9 to -0.04 letters) lay wholly within both the upper and lower margins of the permitted maximum difference (5 Early Treatment Diabetic Retinopathy Study letters). There was no statistically significant difference between groups in any of the secondary outcomes investigated with the exception of the number of laser treatments performed, which was slightly higher in the subthreshold micropulse laser group (mean difference 0.48, 95% confidence interval 0.18 to 0.79; p = 0.002). Base-case analysis indicated no significant difference in the cost per quality-adjusted life-years between groups.A trial in people with ≥ 400 µm diabetic macular oedema comparing anti-vascular endothelial growth factor therapy alone with anti-vascular endothelial growth factor therapy and macular laser applied at the time when central retinal subfield thickness has decreased to < 400 µm following anti-vascular endothelial growth factor injections would be of value because it could reduce the number of injections and, subsequently, costs and risks and inconvenience to patients.The majority of participants enrolled had poorly controlled diabetes.Subthreshold micropulse laser was equivalent to standard threshold macular laser but required a slightly higher number of laser treatments.This trial is registered as EudraCT 2015-001940-12, ISRCTN17742985 and NCT03690050.This project was funded by the National Institute for Health and Care Research ( NIHR ) Health Technology Assessment programme and will be published in full in Health Technology Assessment; Vol. 26, No. 50. See the NIHR Journals Library website for further project information.The retina is a layer at the back of the eye. Its centre is called the macula and is responsible for central vision. Some people with diabetes develop diabetic macular oedema. In diabetic macular oedema fluid leaks from retinal blood vessels and builds up at the macula, resulting in sight loss. Diabetic macular oedema can be mild or severe; this can be determined measuring the thickness of the macula, which is measured in micrometres (µm). One micrometre is one thousandth of a millimetre. In mild diabetic macular oedema, the thickness of the macula increases, but is less than 400 µm. Patients with mild diabetic macular oedema can be treated with a laser and there are two laser types. The standard threshold macular laser has been available for many years. It clears the diabetic macular oedema but produces a ‘burn’ in the retina. The subthreshold micropulse laser is newer. It does not produce a burn but also clears the diabetic macular oedema. The lack of a burn, however, has led to doubts about whether or not this laser works as well as the standard threshold macular laser because ‘no burn’ was taken to mean ‘less benefit’. These doubts led to our establishing the DIAMONDS (DIAbetic Macular Oedema aNd Diode Subthreshold micropulse laser) trial, which compared these two lasers for people with mild diabetic macular oedema. A total of 266 people suitable for either laser joined the study at 16 NHS hospitals across the UK; 133 received standard threshold macular laser and 133 received subthreshold micropulse laser. The choice of laser was determined by chance. The DIAMONDS trial found that the subthreshold micropulse laser was as good as the standard threshold macular laser (i.e. ‘clinically equivalent’) in terms of improving people’s vision, reducing macula thickness, allowing people to meet driving standards and maintaining their quality of life, both in general terms and for vision in particular. There was a small increase (less than one session on average per person) in the number of laser treatment sessions needed with subthreshold micropulse laser. The costs of both laser treatments were about the same." @default.
• W4313209954 created "2023-01-06" @default.
• W4313209954 creator A5000602717 @default.
• W4313209954 creator A5004470262 @default.
• W4313209954 creator A5005781424 @default.
• W4313209954 creator A5012964371 @default.
• W4313209954 creator A5024512128 @default.
• W4313209954 creator A5025519446 @default.
• W4313209954 creator A5030971775 @default.
• W4313209954 creator A5032478480 @default.
• W4313209954 creator A5035891540 @default.
• W4313209954 creator A5035946370 @default.
• W4313209954 creator A5039042181 @default.
• W4313209954 creator A5041103166 @default.
• W4313209954 creator A5042624834 @default.
• W4313209954 creator A5044120519 @default.
• W4313209954 creator A5045273192 @default.
• W4313209954 creator A5050081586 @default.
• W4313209954 creator A5052630877 @default.
• W4313209954 creator A5059290673 @default.
• W4313209954 creator A5062002030 @default.
• W4313209954 creator A5066434934 @default.
• W4313209954 creator A5068981280 @default.
• W4313209954 creator A5077478697 @default.
• W4313209954 creator A5078285058 @default.
• W4313209954 creator A5080966283 @default.
• W4313209954 creator A5083522033 @default.
• W4313209954 creator A5085938978 @default.
• W4313209954 creator A5090676693 @default.
• W4313209954 date "2022-12-01" @default.
• W4313209954 modified "2023-09-30" @default.
• W4313209954 title "Standard threshold laser versus subthreshold micropulse laser for adults with diabetic macular oedema: the DIAMONDS non-inferiority RCT" @default.
• W4313209954 cites W1481978003 @default.
• W4313209954 cites W1499617936 @default.
• W4313209954 cites W1507380480 @default.
• W4313209954 cites W1786299986 @default.
• W4313209954 cites W1896805399 @default.
• W4313209954 cites W1931781407 @default.
• W4313209954 cites W1979808351 @default.
• W4313209954 cites W2010059301 @default.
• W4313209954 cites W2013564592 @default.
• W4313209954 cites W2018585024 @default.
• W4313209954 cites W2021783409 @default.
• W4313209954 cites W2024518620 @default.
• W4313209954 cites W2039033325 @default.
• W4313209954 cites W2044054504 @default.
• W4313209954 cites W2058854776 @default.
• W4313209954 cites W2061823932 @default.
• W4313209954 cites W2067162223 @default.
• W4313209954 cites W2082054485 @default.
• W4313209954 cites W2083896509 @default.
• W4313209954 cites W2086222512 @default.
• W4313209954 cites W2096060458 @default.
• W4313209954 cites W2104306225 @default.
• W4313209954 cites W2148230234 @default.
• W4313209954 cites W2152740900 @default.
• W4313209954 cites W2160745487 @default.
• W4313209954 cites W2164963279 @default.
• W4313209954 cites W2166194526 @default.
• W4313209954 cites W2193621263 @default.
• W4313209954 cites W2289200040 @default.
• W4313209954 cites W2341965208 @default.
• W4313209954 cites W2513305219 @default.
• W4313209954 cites W2513844704 @default.
• W4313209954 cites W2605619962 @default.
• W4313209954 cites W2616361514 @default.
• W4313209954 cites W2617623077 @default.
• W4313209954 cites W2737710660 @default.
• W4313209954 cites W2767876753 @default.
• W4313209954 cites W2869243488 @default.
• W4313209954 cites W2897932241 @default.
• W4313209954 cites W2898493492 @default.
• W4313209954 cites W2900450155 @default.
• W4313209954 cites W2904253296 @default.
• W4313209954 cites W2911426771 @default.
• W4313209954 cites W2942447515 @default.
• W4313209954 cites W2943809429 @default.
• W4313209954 cites W2954522684 @default.
• W4313209954 cites W2971699956 @default.
• W4313209954 cites W3007407869 @default.
• W4313209954 cites W3008931937 @default.
• W4313209954 cites W3097576650 @default.
• W4313209954 cites W3164582772 @default.
• W4313209954 cites W3164889911 @default.
• W4313209954 cites W3172572138 @default.
• W4313209954 cites W4210297421 @default.
• W4313209954 cites W4233230329 @default.
• W4313209954 cites W4292528167 @default.
• W4313209954 cites W4300511274 @default.
• W4313209954 cites W4317390067 @default.
• W4313209954 doi "https://doi.org/10.3310/szki2484" @default.
• W4313209954 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36541393" @default.
• W4313209954 hasPublicationYear "2022" @default.
• W4313209954 type Work @default.
• W4313209954 citedByCount "0" @default.
• W4313209954 crossrefType "journal-article" @default.
• W4313209954 hasAuthorship W4313209954A5000602717 @default.
• W4313209954 hasAuthorship W4313209954A5004470262 @default.

• next